2026齐济投资大会成功举办

Core Viewpoint - The 2026 Qi Ji Investment Conference emphasizes the importance of collaboration among government, academia, and industry to drive innovation in the healthcare sector, highlighting China's potential in the biopharmaceutical industry as a new pillar of economic growth [1][32]. Group 1: Event Overview - The conference, themed "Gathering Momentum, Creating New Journeys," took place in Shanghai and attracted nearly 150 guests, including government leaders, academicians, top scientists, and representatives from leading investment institutions [1]. - The event serves as a platform for deepening strategic cooperation between the Songjiang District and Qi Ji Investment, focusing on the integration of technology, industry, and finance [2]. Group 2: Keynote Speeches - Wang Huajie, Secretary of the Songjiang District Committee, highlighted the district's advantages in the life and health sector, particularly in in vitro diagnostics and medical devices, and emphasized the need for innovation-driven development [2]. - Zhang Li, CEO of Qi Ji Investment, discussed the shift from macro narratives to micro values in the healthcare industry, asserting that China's biopharmaceutical sector is entering a period of significant growth, akin to a "Golden Age" [9]. - Song Ruilin, a senior expert from the China Pharmaceutical Innovation Promotion Association, pointed out the challenges faced by innovative drugs in China, advocating for a multi-tiered payment system to support sustainable industry development [12][13]. Group 3: Industry Insights - The conference featured discussions on various topics, including the integration of industry and ecology, cross-border cooperation, and the role of AI in pharmaceuticals [21][22][24][27]. - Participants noted that China's clinical research capabilities have significantly improved, allowing for more flexible collaboration models between domestic and international pharmaceutical companies [25]. - The importance of a multi-faceted capital allocation strategy was emphasized, with discussions on the roles of state-owned funds, market-oriented funds, and financial institutions in supporting innovative drug development [29]. Group 4: Future Directions - The conference concluded with a call for continuous innovation and collaboration within the healthcare ecosystem, aiming to break traditional boundaries and achieve long-term value creation [32].